Form D · Biotechnology
Lindy Biosciences, Inc.
Morrisville, NC · CIK 0001731038
Offering snapshot reported Mar 19, 2024 · SEC filing
- Reported sold
- $1.71M Offering amount: $2.5M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 12, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 19, 2024 | Initial | $1,709,637 | No comparison | 10 | SEC filing |
| Mar 16, 2022 | Initial | $3,259,946 | No comparison | 29 | SEC filing |
| Jan 22, 2019 | Initial | $547,736 | No comparison | 6 | SEC filing |
| Mar 16, 2018 | Initial | $150,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-508013
Source: Form D, filed Mar 19, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Deborah Bitterfield | Director, Executive, Promoter |
| Omar Flores | Director, Executive |
| Sreekar Gadde | Director |
| Karen Levert | Director |
| Karen Le Vert | Director |
| Joel Whitley | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
627 Davis Drive Suite 400
Morrisville, NC, 27560
Morrisville, NC, 27560